An assay that may predict the development of IgG enhancing allergen-specific IgE binding during birch immunotherapy

Authors


  • Edited by: Michael Wechsler

Correspondence

Prof. Rudolf Valenta, Division of Immunopathology, Department of Pathophysiology and Allergy Research, Center for Pathophysiology, Infectiology and Immunology, Vienna General Hospital, Level 3Q, Medical University of Vienna, Waehringer Gürtel 18-20, A-1090 Vienna, Austria.

Tel.: +43140400/5108

Fax: +43140400/5130

E-mail: rudolf.valenta@meduniwien.ac.at

Abstract

Background

It has been shown that birch pollen immunotherapy can induce IgG antibodies which enhance IgE binding to Bet v 1. We aimed to develop a serological assay to predict the development of antibodies which enhance IgE binding to Bet v 1 during immunotherapy.

Methods

In 18 patients treated by Bet v 1-fragment-specific immunotherapy, the effects of IgG antibodies specific for the fragments on the binding of IgE antibodies to Bet v 1 were measured by ELISA. Blocking and possible enhancing effects on IgE binding were compared with skin sensitivity to Bet v 1 after treatment.

Results

We found that fragment-specific IgG enhanced IgE binding to Bet v 1 in two patients who also showed an increase of skin sensitivity to Bet v 1.

Conclusion

Our results indicate that it may be possible to develop serological tests which predict the induction of unfavourable IgG antibodies enhancing the binding of IgE to Bet v 1 during immunotherapy.

Ancillary